
𝐒𝐓𝐈𝐅𝐄𝐋 𝟐𝟎𝟐𝟔: Oruka Therapeutics' IL-23p19 is showing strong efficacy in p2 psoriasis studies compared to existing products and might be dosed as little as once or twice a year - a key update will read next month. $ORKA Full video: biotechtv.com/post/stifel-20…

















